1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Danaher Corp.

Danaher Corporation is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
H. Lawrence Culp

2200 Pennsylvania Ave NW Ste 800W
Washington, Washington Dc 20037-1731
Phone: 12028280850


Here’s Why Danaher Stock (NYSE:DHR) Dropped Yesterday
Oct 03, 2023 05:26am

Shares of Danaher Corporation (NYSE:DHR) dropped as much as 16% in regular trading yesterday after completing the spinoff of its Veralto unit. DHR …

Danaher slips after completing Veralto spinoff
Oct 02, 2023 17:45pm

No summary available.

Source:Seeking Alpha
Why Shares of Danaher Are Down Monday
Oct 02, 2023 16:21pm

The conglomerate has completed the spinoff of its environmental and applied solutions segment into a new company, Veralto.

Source:The Motley Fool
Should Danaher Investors Sell New Veralto Shares?
Oct 02, 2023 13:27pm

Danaher Corporation completes spin-off of Veralto, its Environmental & Applied Solutions business. Read what DHR and VLTO stock investors need to know.

Source:Seeking Alpha
Danaher, Brooge Energy And Other Big Stocks Moving Lower In Monday''s Pre-Market Session
Oct 02, 2023 10:02am

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. SmileDirectClub, Inc. (NASDAQ: SDC ) shares tumbled 64.1% to $0.1489 in pre-market trading. SmileDirectClub filed for bankruptcy just a few years after its remarkable $1.35 billion IPO. Brooge Energy Limited (NASDAQ: BROG ) shares dipped 9.8% to $5.02 in … Full story available on Benzinga.com

Abcam founder looking at various options amid Danaher takeover - report
Oct 01, 2023 13:00pm

Abcam founder and shareholder Jonathan Milner opposes the company''s sale and is looking at various options. Headwaters Capital is also against the dea.

Source:Seeking Alpha
After Danaher Corp. (NYSE: DHR) Surges -23.34% From Highs, What Will It Look Like?
Sep 30, 2023 12:00pm

During the last session, Danaher Corp. (NYSE:DHR)’s traded shares were 3.22 million, with the beta value of the company hitting 0.81. At the end of the trading day, the stock’s price was $248.10, reflecting an intraday gain of 0.37% or $0.91. The 52-week high for the DHR share is $283.63, that puts it down -14.32 … After Danaher Corp. (NYSE: DHR) Surges -23.34% From Highs, What Will It Look Like? Read More »

Source:Marketing Sentinel
We''re set to receive shares in Danaher''s separated water business. Here''s our plan for the new stock
Sep 29, 2023 14:12pm

Danaher''s (DHR) ability to deliver returns for shareholders appears stronger than ever.

Abcam founder slams £4.5bn sale to US conglomerate Danaher
Sep 28, 2023 21:12pm

Jonathan Milner blasted the ''low ball'' offer for the Cambridge-based company, which is one of the most successful British biotech firms.

Source:Daily Mail Online
Danaher Bears The Brunt Of Macro Woes: Analyst Flags Lower Demand, Reduced Funding & Weakness In China
Sep 27, 2023 19:37pm

KeyBanc Capital Markets analyst Paul Knight reiterated the Overweight rating on Danaher Corporation (NYSE: DHR ), lowering the price target to $300 from $325. Knight notes that after a strong period in 2021 and early 2022, the life science tools sector, including DHR, has been underperforming in FY23. The analyst adds that there have been headwinds due to destocking in consumables used in biological production (such as filters and single-use bags), leading to reduced demand as customers worked down stockpiles in FY23. Additionally, funding for early-stage biotech customers has dried up as exit the pandemic, and weakness in China brought biotech spending to a slow pace during the 2Q23 results period, the analyst cautioned. However, on the positive side, Knight writes Danaher has a high-growth and high-margin profile following the Veralto (VLTO) spin. For … Full story available on Benzinga.com